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PDB44 EFFECTS OF INSULIN THERAPY ON THE DIABETES SYMPTOM CHECKLIST-REVISED (DSC-R): DATA FROM A LARGE INSULIN CLINICAL TRIAL
Nelson L 1 , McLeod LD 1 , Lee LJ J 2 , Hill C 1 , Sweeney C 1 , Sun P 3 , Fahrbach J 2 , Martin S 2 , Weinstock RS 4 1 RTI Health Solutions, Research Triangle Park, NC, USA, 2 Eli Lilly and Company, Indianapolis, IN, USA, 3 Kailo Research Group, Indianapolis, IN, USA, 4 SUNY Upstate Medical University and the Department of Veterans Affairs Medical Center, Syracuse, NY, USA OBJECTIVES: To examine the impact of insulin initiation on the DSC-R in patients with type 2 diabetes (T2D). METHODS: We administered the DSC-R to T2D patients enrolled in a large insulin clinical trial (acronym: DURABLE) at baseline prior to starting insulin and at six months post-insulin initiation. The trial compared the efficacy and safety of insulin initiation with lispro mix 75/25 versus insulin glargine. The DSC-R is a T2D-specifi c measure that assesses the occurrence and the perceived burden of the following eight T2D-related symptoms: hypoglycemic, hyperglycemic, cardiovascular, neuropathic/pain, neuropathic/sensory, psychological/fatigue, psychological/ cognitive, and ophthalmologic/vision. Summary score for each domain ranged from 0-100 with higher scores indicating greater symptom burden. We compared change in mean score (baseline to six months) for two insulin arms combined together. Effect size (ES; cohen's d) and analysis of covariance were used to examine the extent and signifi cance of change. Effect sizes of 0.2, 0.5, and 0.8 represent small, medium, and large degrees of change, respectively. RESULTS: A total of 576 patients completed the DSC-R at both time points. The mean age, duration of diabetes, A1c, and percent female at baseline were 57.0 years, 9.6 years, 8.9%, and 41%, respectively. Baseline mean scores ranged from 24.2 (cardiovascular and neuropathic/pain) to 45.9 (psychological/fatigue). The mean scores at 6 months ranged from 22.6 (ophthalmologic/ vision) to 40.7 (psychological/fatigue). Absolute changes in the mean domain score ranged from 0.6 (neuropathic/sensory) [p 0.45; ES 0.02] to 9.8 (hyperglycemic) [p 0.0001; ES 0.38; small to medium effect]. Other domains with ES 0.20 were psychological/fatigue and psychological/cognitive. CONCLUSIONS: Initiation of insulin therapy was associated with a small to moderate improvement in hyperglycemic symptoms domain. Small effects were also observed in psychological/fatigue and psychological/cognitive domains. Diabetes is a debilitating and common illness that can lead to significant disability. Key patient-reported outcomes are important as they can infl uence productivity and patient health-related quality of life (HRQL). The objectives of the current research were to: (1) assess the current level of treatment satisfaction within existing oral anti-diabetics (OADs) and (2) determine the association between treatment satisfaction and productivity and HRQL. METHODS: The current study design was a cross-sectional web-based survey of adults diagnosed with type 2 diabetes mellitus (T2DM) using OADs, but not insulin. Treatment satisfaction was assessed using the Diabetes Medication Satisfaction questionnaire (DiabMedSat). HRQL was examined with the EQ-5D instrument. The Work Productivity and Activity Impairment (WPAI) and Diabetes Productivity Measure (DPM) questionnaires were used to assess productivity. Pearson's correlations and linear regression models were used to assess strength and direction in association. RESULTS: Of 2,074 survey respondents, 53% were men and mean age was 60 years (SD 10.83). 64% of respondents report being very/extremely satisfi ed with their diabetes treatments. Total DiabMedSat score was 79.5; higher scores were reported with the burden subscale (89.5) versus the effi cacy and symptom (i.e. tolerability) sub-scales (69.8 and 69.5). There was a direct correlation between overall treatment satisfaction and higher EQ-5D scores (r2 0.401, p 0.001), and increased work and life productivity (DPM: r2 0.595 and r2 0.640, p 0.001). Similar correlation results were observed with WPAI. After controlling for patient demographics, treatment satisfaction has greater effects on presenteeism (impairment while working) (WPAI: 0.472, 95% CI: 0.611 to -0.333, p 0.001) than absenteeism (missed work time) (WPAI: 0.057, 95% CI: 0.157 to 0.043, p 0.263). CONCLUSIONS: Among T2DM patients, there is a high level of satisfaction with OAD therapies, though improvements could be made in effi cacy and tolerability. Increases in treatment satisfaction can have a direct improvement on productivity and health-related quality of life.
PDB45 SATISFACTION WITH DIABETES TREATMENTS: IMPACTS ON PATIENT HEALTH-RELATED QUALITY OF LIFE AND PRODUCTIVITY

PDB46 CONTRIBUTIONS OF AND RELATIONSHIP BETWEEN EXPECTATIONS ABOUT AND EXPERIENCES WITH INSULIN THERAPY TO TREATMENT SATISFACTION IN INSULIN-NAÏVE PATIENTS WITH TYPE-2 DIABETES
Naegeli AN g , Hayes RP Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: To assess the relationship between patients' expectations about and experiences with insulin therapy, and how they contribute to overall treatment satisfaction. METHODS: The Expectations about Insulin Therapy (EAITQ) and the Experience with Insulin Therapy Questionnaires (EWITQ) were administered at baseline and endpoint, respectively, to insulin-naïve patients with type-2 diabetes in a randomized controlled trial comparing treatment algorithms for an inhaled insulin. Pearson correlation coeffi cients were calculated between EAITQ and EWITQ scores and patient characteristics and patient reported outcomes measures. Wilcoxon Signed Rank test was used to compare EAITQ and EWITQ item score distributions. Differences between EAITQ and EWITQ scores were calculated to categorize patients into three groups according to the extent to which their expectations about insulin therapy were met by experiences (i.e., not met, met, and exceeded). Oneway analysis of variance with Scheffe post-hoc tests was performed to detect differences in treatment satisfaction scores among the three groups. RESULTS: EAITQ and EWITQ data were available for 240 patients (male: 61% male, age: 58 (mean) years old, diabetes duration: 10 years, HbA1c: 8.4%). More positive expectations were signifi cantly associated with greater self-effi cacy (p 0.01); more positive experiences were significantly associated with shorter diabetes duration, less symptom distress and greater well-being, self-effi cacy, and treatment satisfaction (p 0.01). Overall, patients' experiences with insulin therapy were signifi cantly more positive than their expectations, with 58% of patients' experiences exceeding expectations, 29% experiences met by expectations, and 13% experiences less than expectations. Post-hoc tests indicated that diabetes treatment satisfaction scores were signifi cantly different among the three groups with higher scores associated with the exceeding of expectations by experiences. CONCLUSIONS: Expectations may not independently impact treatment satisfaction, but their relationship with experiences signifi cantly contributes to treatment satisfaction. The EAITQ and EWITQ may be useful tools for clinicians in identifying differences in expectations and experiences concerning insulin therapy.
PDB47 THE ASSOCIATION BETWEEN PATIENT-REPORTED DIABETES SYMPTOMS AND TOLERABILITY ISSUES OF ORAL ANTIDIABETIC AGENTS ON WORK AND LIFE PRODUCTIVITY
Pollack M 1 , Bolge SC 2 , Williams S 1 , Waterman F 3 1 AstraZeneca, Wilmington, DE, USA, 2 Consumer Health Sciences International, Princeton, NJ, USA, 3 Consumer Health Sciences, New York, NY, USA OBJECTIVES: Diabetes symptoms and tolerability issues of existing treatments may affect work productivity, contributing to the overall burden of type-2 diabetes mellitus (T2DM). Objectives were to document the frequency of diabetes symptoms and tolerability issues among existing oral antidiabetic drugs (OAD) and determine their
